Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Nov;26(11):2119-2121.
doi: 10.1111/1756-185X.14845. Epub 2023 Aug 11.

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis

Affiliations
Free article
Editorial

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis

Ping Wu et al. Int J Rheum Dis. 2023 Nov.
Free article
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Weiss PF, Fuhlbrigge RC, von Scheven E, et al. Children with enthesitis-related arthritis and possible benefits from treatments for adults with spondyloarthritis. Arthritis Care Res. 2022;74:10581064.
    1. Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an International Task force. Ann Rheum Dis. 2018;77:819-828.
    1. Stefania N, Giovanni R, Riccardo M, et al. Treatment of psoriatic arthritis with secukinumab: a case series. J Dermatol Treat. 2018;29(Suppl 1):6-8.
    1. Oya K, Ayten A, Sezgin S, et al. An overview of the relationship between juvenile idiopathic arthritis and potential environmental risk factors: do early childhood habits or habitat play a role in the affair? Int J Rheum Dis. 2022;25(12):1376-1385.
    1. Brunner HI, Foeldvari I, Alexeeva E, et al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis. 2023;82(1):154-160.

MeSH terms